Jodie de la Cerda
Primary Care · Greenacres, FLNPI 1336619311
Payments from drug & device makers
Across 151 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$333
- AbbVie$332
- AstraZeneca$319
- Novo Nordisk$315
- Lilly USA, LLC$285
- Takeda Pharmaceuticals U.S.A., Inc.$136
- plus $1K from 23 others
What the payments were for
- Speaking & faculty fees$201%
- Food & beverage$2,81798%
- Education$502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,887 in reported general payments places this provider in the 85th percentile of 725 primary care providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 70 | $87,865 |
| OzempicSemaglutide | 42 | $58,336 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $42,072 |
| JardianceEmpagliflozin | 25 | $26,169 |
| FarxigaDapagliflozin Propanediol | 22 | $23,501 |
| EliquisApixaban | 25 | $22,121 |
| LinzessLinaclotide | 17 | $13,576 |
| RybelsusSemaglutide | 13 | $11,946 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $9,356 |
| EntrestoSacubitril/Valsartan | 11 | $8,453 |
| Verapamil SrVerapamil Hcl | 12 | $2,870 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 74 | $2,409 |
| SynthroidLevothyroxine Sodium | 19 | $1,922 |
| Omeprazole | 126 | $1,835 |
| Atorvastatin Calcium | 280 | $1,518 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $285 | $87,86570 claims |
| Novo NordiskOzempic, Rybelsus | $315 | $70,28255 claims |
| GSKTrelegy Ellipta | $96 | $42,07255 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $319 | $32,85734 claims |
| Boehringer IngelheimJardiance | $38 | $26,16925 claims |
| PfizerEliquis | $333 | $22,12125 claims |
| AbbVieLinzess, Synthroid | $332 | $15,49936 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $12 | $1,331182 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 725 primary care providers in Florida.
Other primary care in Greenacres
- Paul ChanOrlando$447K
- Jenny WestPensacola$80K
- Maria Rodriguez ReyesHialeah$31K
- Railet RodriguezAltamonte Springs$14K
- Kevin HanawayFort Lauderdale$12K
- Kelly ChewningAlachua$11K
- Yolanda PalmeroSaint Cloud$11K
- Erica ClarkCitrus Springs$11K
- Michelle SelvaggiLakewood Ranch$10K
- Kristen DeasonTallahassee$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.